Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $52M (up 14.1% year over year) with net income of −$13M.
Q1 2026 key financials · XBRL
- Revenue
- $52M
- +14.1% YoY
- Net income
- −$13M
- +68.6% YoY
- Operating margin
- 33.6%
- EPS (diluted)
- −$0.67
- +69.7% YoY
Source: XBRL data from the LIGAND PHARMACEUTICALS INC (LGND) Q1 2026 10-Q on SEC EDGAR. USD.
LIGAND PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 revenue $51.7M, up 14% from $45.3M YoY
- Royalty revenue $43.0M, up 56% from $27.5M, led by Filspari at $11.3M
- Captisol revenue $8.7M, down 36% from $13.5M; contract revenue $0.1M, down 97%
- Operating margin 33.6% vs (79.8)% YoY, with operating income $17.4M vs operating loss $36.2M
- Cash, equivalents and short-term investments $779.4M, up $45.9M; $124.4M borrowing capacity remained available
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and exhibits only
- Merger agreement dated April 27, 2026 with XOMA Royalty Corporation
- CFO Rule 10b5-1 arrangement modified February 19, 2026
- No disclosed financial, regulatory, operational, competitive, or liquidity risks in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIGAND PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.